Retatrutide is one of the most famous peptides in metabolic research. It was developed by Eli Lilly and Company.
Retatrutide is a triple receptor agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. Being a triple agonist, it is a unique compound compared to earlier incretin-based therapies. With growing interest in research peptides in 2026, many researchers are looking for to-the-point information about Retatrutide pricing, availability, and research-grade sourcing options.
What Is the Price of Eli Lilly Retatrutide in 2026?
Retatrutide (as of as of September 2026), also know as ” LY3437943″, remains an investigational compound in Phase 3 clinical development. For commercial sale, it has not received FDA approval. As it is not marketed by Eli Lilly commercially, there is currently no official retail pharmacy price for Retatrutide.
Researchers in need of Retatrutide for laboratory studies often obtain research-grade material from peptide suppliers, such as Orion Peptide, that offer the compound for research purposes only.
Retatrutide Price Comparison at Orion Peptides (Sepetember 2026)
| Compound | Price at Orion Peptides | Research Grade |
| Retatrutide 5 mg | $54 | Yes |
| Retatrutide 10 mg | $81 | Yes |
| Retatrutide 20 mg | $146 | Yes |
| Retatrutide 15 mg | $119 | Yes |
| Retatrutide 30mg | $315 | Yes |
Prices listed on the Orion Peptides website as of September 2026 can change with the passage of time.
What Retatrutide is.
Retatrutide, LY3437943, is developed by Eli Lilly. It is an investigational peptide. Unlike other compounds, which activate a single pathway, Retatrutide activates three separate receptor pathways (triple agonist), and they are as follows:
- GLP-1 receptor
- GIP receptor
- Glucagon receptor
Because it affects several metabolic signaling pathways at a time, researchers are studying this triple-agonist mechanism. Through the TRIUMPH Phase 3 program, the compound remains under clinical investigation.
Why Is Retatrutide The Subject of Interest?
Various reasons have contributed to growing and greater scientific interest in Retatrutide:
1. Activity as a Triple-Receptor
Retatrutide is among the first investigational peptides that has combined GLP-1, GIP, and glucagon receptor activation into one molecule. Researchers are trying to figure out how this multi-target approach is different from single- and dual-agonist compounds.
2. Extended Half-Life
According to research data, Retatrutide has a half-life of approximately six days. During experimental protocols, it allows sustained receptor engagement.
3. Continuous Clinical Development
Retatrutide in Phase 3 studies is under evaluation, due to which, in metabolic research, it is one of the most closely followed investigational compounds.
For Retatrutide, why do a lot of Researchers Select Orion Peptides?
In 2026, Orion Peptides became a notable source for research-grade Retatrutide compounds.
Some of the primary reasons for this selection are as follows:
- Different concentration options (5 mg, 10 mg, 20 mg, and 30 mg)
- Third-party testing
- HPLC-verified purity
- Research-grade manufacturing standards
- Bulk pricing discounts on larger orders
- Fast shipping
As per compound listings, Orion Peptides offers Retatrutide with purity levels of at least 98% verified by HPLC testing.
Retatrutide vs Other Research Peptides
| Peptide | Focus of research |
| Retatrutide | Signaling of GLP-1, GIP, and glucagon receptors |
| Tirzepatide | Signaling of GLP-1 and GIP receptors |
| Semaglutide | Signaling of GLP-1 receptor |
| Cagrilintide | Research related to the Amylin pathway |
| AOD-9604 | GH fragment research |
Retatrutide is the subject of interest because now it is one of the few peptides that are investigated as a triple receptor agonist.
Retatrutide Storage Guidelines
Here’s a general storage guideline for retatrutide, based on standard peptide handling practices (it’s still an investigational compound, so always defer to the specific instructions from whoever supplied it):
Unopened / Lyophilized (powder) form
- Store at -20°C to -80°C (freezer) for longest shelf life
- If a freezer isn’t available, refrigeration at 2–8°C is acceptable for shorter-term storage
- Keep away from light — use the original amber/opaque vial or wrap in foil
- Keep sealed and protected from humidity; a desiccant pack helps prevent moisture absorption
- Avoid repeated freeze-thaw cycles of the sealed vial
FAQs
1. Does Eli Lilly directly sell Retatrutide?
No, Retatrutide, currently remains in Phase 3 clinical development and is not marketed by Eli Lilly commercially.
2. What is the current status of Retatrutide? Is Retatrutide FDA-approved?
No. Retatrutide has not received FDA approval as of September 2026, and it is still under clinical investigation.
3. What is the difference between Retatrutide and Semaglutide?
Semaglutide targets only the GLP-1 receptor, while Retatrutide triple receptor agonist and is designed to simultaneously activate GLP-1, GIP, and glucagon receptors.
Summary
Retatrutide, in 2026, remains one of the investigational peptides. Retatrutide has not yet been launched commercially by Eli Lilly; there is no official retail market price.
Researchers who are seeking laboratory-grade Retatrutide often compare vendors based on purity testing, documentation, concentration options, and overall value.
Orion Peptides currently offers Retatrutide in 5 mg, 10 mg,15 mg, 20 mg, and 30 mg formats, with listed prices ranging from $54 to $315 depending on concentration.
Research Use Only: Retatrutide is an investigational compound. It should be used in a closely monitored research environment. It is not approved for human consumption, diagnosis, treatment, or prevention of any disease.
